Vertex Pharmaceuticals Incorporated which can be found using ticker (VRTX) now have 24 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $456.00 and $315.00 suggesting an average Analsyt target price of $388.67. Given that the stocks previous close was at $362.11 this indicates there is a potential upside of 7.3%. It’s also worth noting that there is a 50 day moving average of $354.95 while the 200 day moving average is $334.33. The market cap for the company is 94.15B. The current share price for the company is: $364.79 USD
The potential market cap would be $101,056,222,153 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 28.23, revenue per share of $36.96 and a 15.56% return on assets.
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
